Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
Pulmonary Cell News
Pulmonary Cell News is an online resource dedicated to the topics of respiratory disease, lung cancer, and pulmonary cells.
HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in...
[HUTCHMED ] HUTCHMED announced the completion of patient enrollment of SANOVO, a China Phase III study of ORPATHYS® and TAGRISSO® as a first-line treatment in certain NSCLC patients whose tumors harbor EGFR mutation and MET overexpression.
Coordinating Oncogenesis and Immune Evasion: KPNA2, GOLM1, and TK1 As Novel CAR T-Cell Targets in Lung Adenocarcinoma
[European Journal of Medical Research] Researchers identified three oncogenic drivers, karyopherin α2 (KPNA2), golgi membrane protein 1 (GOLM1) and thymidine kinase 1 (TK1), that are overexpressed in lung adenocarcinoma, spatially enriched in malignant niches and associated with significantly reduced overall survival.
Integrated Molecular and Clinical Characterization of Pulmonary Large Cell Neuroendocrine Carcinoma
[Nature Communications] In a study of 590 patients across two independent cohorts, investigators observed comparable overall survival across treatment regimens in pulmonary large cell neuroendocrine carcinoma without unexpected adverse events.
First-Line Sacituzumab Tirumotecan with Tagitanlimab in Advanced Non-Small-Cell Lung Cancer: A Phase 2 Trial
[Nature Medicine] Researchers reported the initial findings from the ongoing Phase I OptiTROP-Lung01 study, evaluating the combination of sacituzumab tirumotecan and tagitanlimab, an anti-PD-L1 antibody, as first-line therapy in patients with advanced or metastatic NSCLC who lack actionable genomic alterations.
TRIM32 Promotes Anoikis Resistance and Metastasis in NSCLC by Degrading CHEK2 to Enhance IL-6 Secretion
[Cell Death & Differentiation] Scientists demonstrated that TRIM32 enhances both anoikis resistance and metastasis in NSCLC.
Lung Cell Fates during Influenza
[Cell Research] The authors discuss recent advances in our understanding of the cell types that are targeted by influenza A viruses (IAV), the consequences of IAV infection on the biology of these cells, and their contribution to lung pathology in influenza.
Bifidobacterium animalis Suppresses Non-Small Cell Lung Cancer Progression and Modulates Tumor Immunity through Indole-3-Acetic Acid
[Cell Reports] Researchers identified distinct disparity in the gut microbiota composition between patients with NSCLC and healthy controls, with Bifidobacterium animalis being markedly decreased in NSCLC.
AFF4 Promotes Tumor Progression and Cisplatin Resistance by Modulating the PTEN/PI3K/AKT/mTOR Axis to Accelerate Glycolysis in Lung Adenocarcinoma
[Cell & Bioscience] AF4/FMR2 family member 4 (AFF4) expression was assessed in LUAD cells and tissues using bioinformatics analysis, western blotting, and immunohistochemical staining.
KLF1 Promotes Non-Small Cell Lung Cancer Cell Proliferation and Invasion by Upregulating the LINC02159/DYNC1H1 Pathway
[Kaohsiung Journal of Medical Sciences] Clinical samples from NSCLC patients were collected, after which the expression levels of KLF1, LINC02159, and dynein cytoplasmic 1 heavy chain 1 (DYNC1H1) in tissues and cells were initially detected, and NSCLC cell proliferation and invasion were measured when KLF1 was up- or downregulated.
MAIA Biotechnology Receives FDA’s Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer
[MAIA Biotechnology, Inc.] MAIA Biotechnology, Inc. announced that the US FDA has granted Fast Track designation for ateganosine for the treatment of NSCLC.
NMPA Accepts sNDA for Ivonescimab in Combination with Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer
[AKeso, Inc (BioSpace)] Akeso, Inc. announced that the National Medical Products Administration (NMPA) has accepted the supplementary New Drug Application for ivonescimab in combination with chemotherapy as a first-line treatment for advanced squamous NSCLC.
Genetic Variation in the Activity of a TREM2-P53 Signaling Axis Determines Oxygen-Induced Lung Injury
[Nature Immunology] Using genetically diverse mouse models, scientists found that hyperoxia-sensitive mice exhibit a distinct innate immune response compared to resilient strains.
Spurred by advances in the modeling of the airway epithelium, Pulmonary Cell News was launched in 2012 to help scientists stay at the forefront of cutting edge research. Every week, our editors hand-select the most recent, top scientific journal articles on the topics of pulmonary cells, lung cancers, and respiratory diseases such as COPD and asthma. We also highlight current job postings and upcoming events to keep the global research community connected!
